Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Weekly
Analytics
Project Updates and Milestones news
(page 2)
26 February 2026
Eni Reports Strong 2025 Financial and Strategic Progress
Strong Q4 results with 35% net income growth. Major projects launched, production up 7%. LNG expansion, biofuels growth, and strategic partnerships enhance resilience and shareholder returns.
26 February 2026
EEW Advances Flue Gas Cleaning Modernization in Helmstedt
EEW invests in flue gas cleaning to meet strict emissions, enhance environmental performance, and ensure long-term site viability during ongoing operations in Helmstedt.
26 February 2026
RWE Expands Italy's Wind and Solar Capacity to 235 MW
RWE doubles its renewable projects in Italy, adding 123 MW in 2026. New wind and solar projects will power 190,000 homes, with more developments planned.
25 February 2026
ViiV Healthcare: Lotivibart Shows 94% Viral Suppression in Long-Acting HIV Treatment
Lotivibart, combined with CAB LA, maintained viral suppression in 94% of participants. Study progresses to test twice-yearly dosing. Well-tolerated with fewer adverse events in IV group.
25 February 2026
Merck Animal Health's NUMELVI: FDA-Approved JAK Inhibitor for Canine Allergic Dermatitis
FDA approves NUMELVI for dogs 6+ months, a JAK inhibitor for allergic dermatitis, offering rapid itch relief and easy dosing. Available spring 2026.
25 February 2026
Merck Presents Phase 3 Trial Results for HIV-1 Treatment DOR/ISL at CROI 2026
DOR/ISL shows non-inferiority and similar safety to BIC/FTC/TAF in HIV-1 treatment-naïve adults and maintains suppression in those switching from other therapies.
News type
New Projects and Expansions
New Projects and Expansions
Project Updates and Milestones
Project Updates and Milestones
Mergers, Acquisitions, and Partnerships
Mergers, Acquisitions, and Partnerships
Innovation and Product Development
Innovation and Product Development
Operational Changes and Investments
Operational Changes and Investments
Sustainability and Environmental Initiatives
Sustainability and Environmental Initiatives
Financial Performance and Strategy
Financial Performance and Strategy
Executive Appointments and Governance Changes
Executive Appointments and Governance Changes
Regulatory and Compliance Updates
Regulatory and Compliance Updates
Workforce and Corporate Social Responsibility (CSR)
Workforce and Corporate Social Responsibility (CSR)
Crisis and Risk Management
Crisis and Risk Management
The right choices in the European chemical industry
Save time with
chemXplore Analytics
Learn more
25 February 2026
MOL and Janaf Agree on Adria Pipeline Capacity Tests
Long-term tests will assess Adria pipeline capacity. MOL seeks clarity on Russian oil shipments and criticizes Janaf's pricing. Two competitive routes are vital for regional supply security.
25 February 2026
Regulation Essential for OCCS Investment in Maritime Decarbonization
A DNV report highlights the need for clear regulations to advance OCCS technology, crucial for maritime decarbonization, with pilot projects showing technical feasibility and economic potential.
25 February 2026
Statkraft and OX2 Partner on Finland Battery Storage Optimization
Statkraft will optimize two large-scale battery systems in Finland, enhancing grid stability and renewable integration, starting in 2028 with a seven-year agreement.
25 February 2026
Worley Wins EPCM Contract for Danish Hydrogen Pipeline
Worley to provide EPCM services for Denmark's hydrogen pipeline, linking green hydrogen production with Germany, enhancing energy security and supporting the green transition.
24 February 2026
Technip Energies Secures Contract for Mozambique Coral Norte LNG Project
Coral Norte, Mozambique's second FLNG, progresses with proven design, enhancing efficiency and LNG capacity, following Coral Sul's success.
24 February 2026
Johnson & Johnson Seeks FDA Approval for IMAAVY® to Treat wAIHA
IMAAVY® targets wAIHA by blocking FcRn, reducing IgG. Phase 2/3 study shows improved hemoglobin and fatigue.
24 February 2026
Novo Nordisk's UBT251 Achieves 19.7% Weight Loss in Phase 2 China Trial
UBT251, a triple agonist, showed significant weight loss and improved health markers in a Chinese phase 2 trial, with a safe and well-tolerated profile.
24 February 2026
Rompetrol Rafinare Schedules Turnaround for Petromidia and Vega Refineries
Petromidia and Vega refineries will halt operations for a 20-day scheduled maintenance, focusing on inspections, equipment cleaning, and component replacements to ensure safety and efficiency.
23 February 2026
Johnson & Johnson's RYBREVANT® Approved for New Dosing Options in EGFR-Mutated Lung Cancer
European Commission approves subcutaneous RYBREVANT® for flexible dosing in advanced EGFR-mutated NSCLC, offering reduced clinic time and fewer reactions.
23 February 2026
LyondellBasell Updates 2030 Sustainability Goals
LYB revises 2030 goals: 32% emissions cut, 800,000 tons recycled polymers. Focus on circular, low-carbon growth, capital discipline, and sustainability.
23 February 2026
Sasol Advances Strategic Goals, Meets CMD Targets
Sasol reports stable turnover, improved production, and reduced costs. Despite lower earnings, free cash flow rose, supported by strategic initiatives and disciplined management.
23 February 2026
Novo Nordisk: CagriSema Shows 23% Weight Loss in Trial, Misses Primary Endpoint
CagriSema achieved 23% weight loss in 84 weeks but didn't match tirzepatide. Further trials will explore higher doses. Safe profile with mild gastrointestinal effects.
23 February 2026
Sasol Advances Strategic Goals, Meets CMD Targets
Despite a challenging macro environment, Sasol improved production, managed costs, and increased free cash flow, while advancing its Grow and Transform strategy.
21 February 2026
Johnson & Johnson's TREMFYA® Shows Sustained Remission in Ulcerative Colitis Over 3 Years
TREMFYA® maintains clinical, endoscopic, and histologic outcomes in ulcerative colitis through 140 weeks, with high patient retention and no new safety concerns.
20 February 2026
Chugai Launches Japan's First Regenerative Treatment for Duchenne Muscular Dystrophy
ELEVIDYS, a one-time therapy for DMD, targets ambulatory patients aged 3-7. Safety measures and post-marketing studies are in place following reports of liver failure cases.
20 February 2026
Eni Launches Ndungu Full-Field Offshore Angola
Ndungu full-field starts production offshore Angola, boosting output to 60,000 barrels/day. Part of Agogo IWH, it enhances Angola's oil capacity and aligns with low-carbon goals.
20 February 2026
RWE and Vestas Sign Turbine Deal for Vanguard West Offshore Wind Farm
92 turbines to power Vanguard West, with commissioning in 2029. Final investment decision expected in summer 2026. Project to power 1.5 million UK homes.
20 February 2026
MGC Halts Construction at Dutch Facility
Construction of the MXDA facility in the Netherlands is discontinued due to cost, delays, and market conditions. Equipment removal is planned by 2029. Financial impacts are under review.
20 February 2026
Roche's Giredestrant NDA Accepted by FDA for Advanced Breast Cancer
FDA accepts giredestrant NDA based on phase III data showing reduced disease progression risk in ER-positive breast cancer. Decision expected by December 18, 2026.
20 February 2026
MOL Group Q4 2025 Results: Strong Downstream and Consumer Services Boost Performance
Upstream struggles amid tough conditions, while Downstream and Consumer Services thrive. Profit before tax drops 11% to USD 1.3B. 2026 guidance set at USD 1.5B.
20 February 2026
MOL Group Q4 and 2025 Results Released
Profit before tax fell 11% to USD 1.3B. Upstream faced challenges, while downstream grew. 2026 profit guidance set at USD 1.5B. Transition to holding structure and renewable expansion noted.
19 February 2026
Asahi Kasei's Thin-Film Hall Elements Earn IEEE Milestone Recognition
Commercialized in 1983, thin-film Hall elements revolutionized magnetic sensors, enhancing electronics and energy efficiency, with over 50 billion units shipped globally.
19 February 2026
Genentech's Venclexta and Acalabrutinib Combo Approved by FDA for Untreated CLL
FDA approves all-oral, fixed-duration regimen for CLL, reducing treatment time. AMPLIFY study shows 35% lower risk of progression or death compared to chemoimmunotherapy.
19 February 2026
Velocys Achieves 30% Cost Reduction in microFTL™ Technology Deployment
Standardisation and delivery efficiencies enhance capital efficiency for Altalto and NovaSAF 1 projects, advancing them toward final engineering and investment decisions.
← Previous
Next →
